



### www.predict.net



# **Prediction BioSciences**

- Founded in 2009
- 'theranostics'- drug/diagnostic combinations
- Oncology and Neuro/Cardiovascular indications
- Using molecular markers to determine progression or safety/efficacy
- Novel approach
  - Advanced mathematical (informatic) methods
    - Statistical pattern recognition
    - Intelligently combine multiple markers/features into accurate predictive algorithms



## Stroke Theranostic

## RapidResponse c-Fn<sup>™</sup> Enhanced thrombolytic



# Hemorrhagic Transformation

• Occurs in 30-50% of all thrombolytictreated patients

Severity	Mortality/Severe disability rate	% of treated patients
HI-1	<10%	10-15
HI-2	10-20%	5-15
PH-1	40-50%	3-10
PH-2	60-75%	6-11



### RapidResponse c-Fn™

### Cellular Fibronectin (c-Fn)

- Adhesive dimeric glycoprotein
- Fibronectin family
- Usually confined to vascular endothelium

No Vascular Damage Low plasma c-Fn level




Vascular Damage Increased plasma c-Fn level





# c-Fn Single Marker Test

#### Plasma c-Fn Levels




# Insight<sup>™</sup> Dx BREAST CANCER PROFILE



### Insight<sup>™</sup> Dx Breast Cancer Profile: parameters and algorithm

- Molecular markers (8 selected from >60 studied)
  - IHC
    - ERPGR
    - ERBB2/HER2
    - BCL2
    - CDKN1B/p27/Kip1
    - EGFR
    - TP53
  - ISH
    - MYC
- Clinicopathologic data
  - tumor grade
  - tumor size
  - lymph node status (pN)
- Algorithm
  - Personalized risk of recurrence score (0 to 10+)
    - Risk category (e.g., low vs. high)
    - Likelihood of future event (e.g., distant metastasis, diseaserelated death, and/or overall survival)





### Sample Test Report

